Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew K Labriola

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Clinical Advances in Hematology & Oncology : H&O|September 20, 2022
How we manage griefAnthony N Galanos, Matthew K Labriola
BMJ Case Reports|August 4, 2025
Paraneoplastic cerebellitis with Kelch-like protein 11 antibodies as an initial presentation for testicular seminomaJoshua S Mercer, Elisha Myers, Matthew K Labriola
BMJ Case Reports|January 30, 2023
Foreign accent syndrome as a heralding manifestation of transformation to small cell neuroendocrine prostate cancerAmanda Broderick, Matthew K Labriola, Neal Shore, et al.
Prostate Cancer and Prostatic Diseases|November 10, 2020
Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapiesMatthew K Labriola, Saad Atiq, Nathan Hirshman, et al.
AJOB Empirical Bioethics|September 27, 2017
Consent for organ donation after circulatory death at U.S. transplant centersGeorge E Hardart, Matthew K Labriola, Kenneth Prager, et al.
BMJ Case Reports|October 5, 2022
Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenomaKatelyn Nazaneen Seale, Matthew K Labriola, Xiaoyin Sara Jiang, et al.
BMJ Case Reports|January 18, 2023
Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline <i>CHEK2</i> mutationBenjamin T Berger, Matthew K Labriola, Emmanuel S Antonarakis, et al.
Clinical Genitourinary Cancer|March 13, 2019
Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell CarcinomaMatthew K Labriola, Kristen A Batich, Jason Zhu, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|April 11, 2025
Grief Among Oncology Providers: Prevalence and Association with BurnoutShannon R McGue, Cameron J Oswalt, Benjamin T Berger, et al.
Clinical Genitourinary Cancer|June 3, 2020
PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial CarcinomaLandon C Brown, Jason Zhu, Matthew K Labriola, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Clinical Advances in Hematology & Oncology : H&O|September 20, 2022
How we manage griefAnthony N Galanos, Matthew K Labriola
BMJ Case Reports|August 4, 2025
Paraneoplastic cerebellitis with Kelch-like protein 11 antibodies as an initial presentation for testicular seminomaJoshua S Mercer, Elisha Myers, Matthew K Labriola
BMJ Case Reports|January 30, 2023
Foreign accent syndrome as a heralding manifestation of transformation to small cell neuroendocrine prostate cancerAmanda Broderick, Matthew K Labriola, Neal Shore, et al.
Prostate Cancer and Prostatic Diseases|November 10, 2020
Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapiesMatthew K Labriola, Saad Atiq, Nathan Hirshman, et al.
AJOB Empirical Bioethics|September 27, 2017
Consent for organ donation after circulatory death at U.S. transplant centersGeorge E Hardart, Matthew K Labriola, Kenneth Prager, et al.
BMJ Case Reports|October 5, 2022
Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenomaKatelyn Nazaneen Seale, Matthew K Labriola, Xiaoyin Sara Jiang, et al.
BMJ Case Reports|January 18, 2023
Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline <i>CHEK2</i> mutationBenjamin T Berger, Matthew K Labriola, Emmanuel S Antonarakis, et al.
Clinical Genitourinary Cancer|March 13, 2019
Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell CarcinomaMatthew K Labriola, Kristen A Batich, Jason Zhu, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|April 11, 2025
Grief Among Oncology Providers: Prevalence and Association with BurnoutShannon R McGue, Cameron J Oswalt, Benjamin T Berger, et al.
Clinical Genitourinary Cancer|June 3, 2020
PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial CarcinomaLandon C Brown, Jason Zhu, Matthew K Labriola, et al.
Pageof 2